Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a global pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for endocrine diseases, today announced that the companies have entered into a definitive agreement under which Vertex will acquire Crinetics for $85.00 per share in cash, for a total equity value of approximately $10.0 billion, or approximately $8.8 billion net of estimated cash acquired. The transaction was unanimously approved by both the Vertex and Crinetics Boards of Directors and is anticipated to close in the third quarter of 2026.

Turn Therapeutics, Inc. (NASDAQ: TTRX), a clinical-stage biotechnology company developing targeted, non-systemic therapies for inflammatory skin diseases, today announced the completion of a comprehensive interim analysis of its ongoing adaptive Phase 2 clinical trial evaluating GX-03 for the treatment of atopic dermatitis.

The Middleby Corporation (NASDAQ: MIDD) today announced that it has completed the previously announced spin-off of its Food Processing business, now operating as Midera Food Processing, Inc. (“Midera”). Shares of Midera common stock will begin trading “regular way” on The Nasdaq Stock Market under the ticker symbol “MFP,” effective at the market opening on July 7, 2026.

Issued on behalf of General Fusion Inc.Spring Valley Acquisition Corp. III (NASDAQ: SVAC) completed its shareholder vote July 6, 2026 approving the business combination with General Fusion Inc., which at closing would create the combined entity General Fusion Group Ltd. and, subject to listing approval, trade on Nasdaq  under the symbol "GFUZ", days after Canada named fusion in its new national nuclear energy strategy.VANCOUVER, BC, July 7, 2026 /PRNewswire/ -- American News Group News Commentary, Fusion energy has spent decades as the perennial promise of clean power, always described as years away. That framing is being tested in real time. ...